MT-RNR1 holds the instructions for MOTS-c.
The body makes this small peptide. The interesting part is how it handles fuel; the unanswered part is what giving more would do for people.
An interesting idea still needs testing.
MOTS-c is a short chain of amino acids, the building blocks of proteins. Its instructions sit within MT-RNR1, a gene in mitochondrial DNA. Mitochondria help cells turn fuel into usable energy. That unusual origin helps explain the interest.
Use
sugar in muscle
In the early cell and mouse work, MOTS-c helped mice handle sugar and resist some effects of a high-fat diet. Muscle fuel use is the part we find worth following. The mice don’t tell us whether a person would lose weight or feel less tired.
The biology can be interesting without already being a treatment. We don’t need to rush it into one.
Store
the distinction between measuring and treating
Researchers have measured the body’s own MOTS-c around exercise. They also tested performance in mice given the peptide. Those are two different experiments, even when they share a paper.
A blood measurement in someone who exercised isn’t a test of an injection. Calling MOTS-c an exercise replacement skips the very step that needs proving.
Respond
to the safety gap
In its May 2026 evaluation, FDA reviewers found no human safety studies and raised concerns about immune reactions. Injected peptides can clump or contain impurities that the body may react to. These are potential risks, not a measured list of MOTS-c side effects.
“The body makes it” doesn’t settle the question. Making a peptide inside the body and injecting a preparation are different situations.
The missing result matters.
MOTS-c hasn’t demonstrated human benefits for fat loss, stamina or blood sugar. As of September 2026, a registered trial in adults with prediabetes and extra weight had no posted results. Registration describes what researchers plan to test. It isn’t an answer about whether treatment works.
What prescription access can tell you.
MOTS-c has no FDA approval. FDA’s page current as of April 22, 2026 lists it among nominations that were withdrawn, with safety concerns still beside it. Withdrawal gives no clearance to compound it. A compounded medicine is prepared by a pharmacist or doctor.
Providers at Promise Peptides (mypromise.com) prescribe compounded MOTS-c. A licensed U.S. provider reviews your request and decides whether a prescription fits; you may not qualify. Care is limited to the United States. Compounded medicines are not FDA-approved.
That route answers an access question. It doesn’t supply the missing evidence of benefit.